274 related articles for article (PubMed ID: 22043992)
1. New targeted therapies for anaplastic thyroid cancer.
Antonelli A; Fallahi P; Ulisse S; Ferrari SM; Minuto M; Saraceno G; Santini F; Mazzi V; D'Armiento M; Miccoli P
Anticancer Agents Med Chem; 2012 Jan; 12(1):87-93. PubMed ID: 22043992
[TBL] [Abstract][Full Text] [Related]
2. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788.
Kim S; Schiff BA; Yigitbasi OG; Doan D; Jasser SA; Bekele BN; Mandal M; Myers JN
Mol Cancer Ther; 2005 Apr; 4(4):632-40. PubMed ID: 15827337
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
Schiff BA; McMurphy AB; Jasser SA; Younes MN; Doan D; Yigitbasi OG; Kim S; Zhou G; Mandal M; Bekele BN; Holsinger FC; Sherman SI; Yeung SC; El-Naggar AK; Myers JN
Clin Cancer Res; 2004 Dec; 10(24):8594-602. PubMed ID: 15623643
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
[TBL] [Abstract][Full Text] [Related]
5. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A; Bocci G; Fallahi P; La Motta C; Ferrari SM; Mancusi C; Fioravanti A; Di Desidero T; Sartini S; Corti A; Piaggi S; Materazzi G; Spinelli C; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2014 Apr; 99(4):E572-81. PubMed ID: 24423321
[TBL] [Abstract][Full Text] [Related]
6. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL
Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179
[TBL] [Abstract][Full Text] [Related]
7. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
Savvides P; Nagaiah G; Lavertu P; Fu P; Wright JJ; Chapman R; Wasman J; Dowlati A; Remick SC
Thyroid; 2013 May; 23(5):600-4. PubMed ID: 23113752
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11.
Kim S; Yazici YD; Barber SE; Jasser SA; Mandal M; Bekele BN; Myers JN
Head Neck; 2006 May; 28(5):389-99. PubMed ID: 16388530
[TBL] [Abstract][Full Text] [Related]
10. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
12. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.
Copland JA; Marlow LA; Kurakata S; Fujiwara K; Wong AK; Kreinest PA; Williams SF; Haugen BR; Klopper JP; Smallridge RC
Oncogene; 2006 Apr; 25(16):2304-17. PubMed ID: 16331265
[TBL] [Abstract][Full Text] [Related]
13. The PLK1 inhibitor GSK461364A is effective in poorly differentiated and anaplastic thyroid carcinoma cells, independent of the nature of their driver mutations.
Russo MA; Kang KS; Di Cristofano A
Thyroid; 2013 Oct; 23(10):1284-93. PubMed ID: 23509868
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
15. New approaches to thyroid cancer.
Cohen EE
Clin Adv Hematol Oncol; 2012 Apr; 10(4):255-6. PubMed ID: 22706487
[No Abstract] [Full Text] [Related]
16. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
17. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Aiello A; Pandini G; Frasca F; Conte E; Murabito A; Sacco A; Genua M; Vigneri R; Belfiore A
Endocrinology; 2006 Sep; 147(9):4463-75. PubMed ID: 16777971
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.
Hoffmann S; Burchert A; Wunderlich A; Wang Y; Lingelbach S; Hofbauer LC; Rothmund M; Zielke A
Endocrine; 2007 Apr; 31(2):105-13. PubMed ID: 17873319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]